Outcomes Associated With Left Ventricular Assist Devices Among Recipients With and Without End-stage Renal Disease

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Left ventricular assist devices (LVADs) are used as both a bridge to heart transplant and destination therapy for patients with advanced heart failure,1 and have been shown to prolong survival and improve quality of life.1-3 The Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) trial demonstrated that LVAD placement as destination therapy improved survival compared with medical therapy alone.1 In 2008—fueled by advances in LVAD technology, scarcity of donor hearts,1 and a growing number of patients who are ineligible for heart transplantation due to comorbidity4—the US Food and Drug Administration approved the use of LVADs as destination therapy for advanced heart failure, paving the way for expansion in the use of these devices.5-7

This publication has 28 references indexed in Scilit: